{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:46:28Z","timestamp":1791423988003,"version":"4.3.3"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T00:00:00Z","timestamp":1307404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/nrrheum.2011.76","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T11:24:01Z","timestamp":1307445841000},"page":"391-398","source":"Crossref","is-referenced-by-count":303,"title":["Anti-CCP antibodies: the past, the present and the future"],"prefix":"10.1038","volume":"7","author":[{"given":"Walther J.","family":"van Venrooij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce J. B. C.","family":"van Beers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ger J. M.","family":"Pruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,7]]},"reference":[{"key":"BFnrrheum201176_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI1316","volume":"101","author":"GA Schellekens","year":"1998","unstructured":"Schellekens, G. A., de Jong, B. A., van den Hoogen, F. H., van de Putte, L. B. & van Venrooij, W. J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101, 273\u2013281 (1998).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201176_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens, G. A. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43, 155\u2013163 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/art.20044","volume":"50","author":"FA van Gaalen","year":"2004","unstructured":"van Gaalen, F. A. et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 50, 709\u2013715 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR4","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741\u20132749 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.autrev.2006.03.008","volume":"6","author":"WJ van Venrooij","year":"2006","unstructured":"van Venrooij, W. J., Zendman, A. J. & Pruijn, G. J. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun. Rev. 6, 37\u201341 (2006).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201176_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/ard.2006.051391","volume":"65","author":"J Avouac","year":"2006","unstructured":"Avouac, J., Gossec, L. & Dougados, M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 65, 845\u2013851 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/ar2903","volume":"12","author":"GJ Pruijn","year":"2010","unstructured":"Pruijn, G. J., Wiik, A. & van Venrooij, W. J. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res. Ther. 12, 203 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR8","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/ard.2009.124537","volume":"69","author":"D van der Woude","year":"2010","unstructured":"van der Woude, D. et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann. Rheum. Dis. 69, 1554\u20131561 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR9","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR10","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1002\/art.27580","volume":"62","author":"T Neogi","year":"2010","unstructured":"Neogi, T. et al. The 2010 American College of Rheumatology\/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report. Arthritis Rheum. 62, 2582\u20132591 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/art.30100","volume":"63","author":"MP van der Linden","year":"2011","unstructured":"van der Linden, M. P., Knevel, R., Huizinga, T. W. & van der Helm-van Mil, A. H. Classification of rheumatoid arthritis\u2014comparison of the 1987 ACR and 2010 ACR\/EULAR criteria. Arthritis Rheum. 63, 37\u201342 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.23.4.302","volume":"23","author":"RL Nienhuis","year":"1964","unstructured":"Nienhuis, R. L. & Mandema, E. A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann. Rheum. Dis. 23, 302\u2013305 (1964).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1083\/jcb.101.4.1257","volume":"101","author":"BA Dale","year":"1985","unstructured":"Dale, B. A., Holbrook, K. A., Kimball, J. R., Hoff, M. & Sun, T. T. Expression of epidermal keratins and filaggrin during human fetal skin development. J. Cell Biol. 101, 1257\u20131269 (1985).","journal-title":"J. Cell Biol."},{"key":"BFnrrheum201176_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/ard.50.9.611","volume":"50","author":"RM Hoet","year":"1991","unstructured":"Hoet, R. M., Boerbooms, A. M., Arends, M., Ruiter, D. J. & van Venrooij, W. J. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann. Rheum. Dis. 50, 611\u2013618 (1991).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2249.1991.tb08124.x","volume":"84","author":"RM Hoet","year":"1991","unstructured":"Hoet, R. M., Voorsmit, R. A. & van Venrooij, W. J. The perinuclear factor, a rheumatoid arthritis-specific autoantigen, is not present in keratohyalin granules of cultured buccal mucosa cells. Clin. Exp. Immunol. 84, 59\u201365 (1991).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201176_CR16","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1172\/JCI116713","volume":"92","author":"M Simon","year":"1993","unstructured":"Simon, M. et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called \u201cantikeratin antibodies,\u201d autoantibodies specific for rheumatoid arthritis. J. Clin. Invest. 92, 1387\u20131393 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201176_CR17","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI117969","volume":"95","author":"M Sebbag","year":"1995","unstructured":"Sebbag, M. et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 95, 2672\u20132679 (1995).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201176_CR18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4049\/jimmunol.162.1.585","volume":"162","author":"E Girbal-Neuhauser","year":"1999","unstructured":"Girbal-Neuhauser, E. et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J. Immunol. 162, 585\u2013594 (1999).","journal-title":"J. Immunol."},{"key":"BFnrrheum201176_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cair.2003.11.001","volume":"4","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar, E. R. & van Venrooij, W. J. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin. Applied Immunol. Rev. 4, 239\u2013262 (2004).","journal-title":"Clin. Applied Immunol. Rev."},{"key":"BFnrrheum201176_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.autrev.2010.08.009","volume":"10","author":"AS Wiik","year":"2010","unstructured":"Wiik, A. S., van Venrooij, W. J. & Pruijn, G. J. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun. Rev. 10, 90\u201393 (2010).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201176_CR21","first-page":"378","volume-title":"From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies: Report on the 8th Dresden Symposium on Autoantibodies held in Dresden on September 12\u201315, 2007","author":"JJBC van Beers","year":"2007","unstructured":"van Beers, J. J. B. C., Zendman, A. J. W., van Venrooij, W. J. & Pruijn, G. J. M. in From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies: Report on the 8th Dresden Symposium on Autoantibodies held in Dresden on September 12\u201315, 2007. Ch. 7 (eds Conrad, K. et al.) 378\u2013388 (Pabst Science Publishers, Lengerich, 2007)."},{"key":"BFnrrheum201176_CR22","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1002\/art.20584","volume":"50","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar, E. R. et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 50, 3485\u20133494 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","volume":"373","author":"L Klareskog","year":"2009","unstructured":"Klareskog, L., Catrina, A. I. & Paget, S. Rheumatoid arthritis. Lancet 373, 659\u2013672 (2009).","journal-title":"Lancet"},{"key":"BFnrrheum201176_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4049\/jimmunol.171.2.538","volume":"171","author":"JA Hill","year":"2003","unstructured":"Hill, J. A. et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 171, 538\u2013541 (2003).","journal-title":"J. Immunol."},{"key":"BFnrrheum201176_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1084\/jem.20072051","volume":"205","author":"JA Hill","year":"2008","unstructured":"Hill, J. A. et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J. Exp. Med. 205, 967\u2013979 (2008).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201176_CR26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/art.27366","volume":"62","author":"D van der Woude","year":"2010","unstructured":"van der Woude, D. et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum. 62, 1236\u20131245 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR27","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1002\/art.27594","volume":"62","author":"EA James","year":"2010","unstructured":"James, E. A. et al. HLA-DR1001 presents \u201caltered-self\u201d peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum. 62, 2909\u20132918 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/rheumatology\/kep338","volume":"49","author":"A Gyetvai","year":"2010","unstructured":"Gyetvai, A. et al. New classification of the shared epitope in rheumatoid arthritis: impact on the production of various anti-citrullinated protein antibodies. Rheumatology (Oxford) 49, 25\u201333 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201176_CR29","doi-asserted-by":"publisher","first-page":"R303","DOI":"10.1186\/ar1187","volume":"6","author":"E Berglin","year":"2004","unstructured":"Berglin, E. et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res. Ther. 6, R303\u2013R308 (2004).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00109-008-0437-9","volume":"87","author":"L Klareskog","year":"2009","unstructured":"Klareskog, L., Wedren, S. & Alfredsson, L. On the origins of complex immune-mediated disease: the example of rheumatoid arthritis. J. Mol. Med. 87, 357\u2013362 (2009).","journal-title":"J. Mol. Med."},{"key":"BFnrrheum201176_CR31","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar3051","volume":"12","author":"SY Bang","year":"2010","unstructured":"Bang, S. Y. et al. Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study. Arthritis Res. Ther. 12, R115 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/ar2504","volume":"10","author":"WJ van Venrooij","year":"2008","unstructured":"van Venrooij, W. J. & Pruijn, G. J. An important step towards completing the rheumatoid arthritis cycle. Arthritis Res. Ther. 10, 117 (2008).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1146\/annurev.immunol.26.021607.090244","volume":"26","author":"L Klareskog","year":"2008","unstructured":"Klareskog, L., Ronnelid, J., Lundberg, K., Padyukov, L. & Alfredsson, L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26, 651\u2013675 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum201176_CR34","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/art.22817","volume":"56","author":"H Bang","year":"2007","unstructured":"Bang, H. et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 56, 2503\u20132511 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.23188","volume":"58","author":"L Mathsson","year":"2008","unstructured":"Mathsson, L. et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 58, 36\u201345 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR36","doi-asserted-by":"publisher","first-page":"R122","DOI":"10.1186\/ar2011","volume":"8","author":"B Vander Cruyssen","year":"2006","unstructured":"Vander Cruyssen, B. et al. Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res. Ther. 8, R122 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR37","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1373\/clinchem.2007.087569","volume":"53","author":"N Bizzaro","year":"2007","unstructured":"Bizzaro, N., Tonutti, E., Tozzoli, R. & Villalta, D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin. Chem. 53, 1527\u20131533 (2007).","journal-title":"Clin. Chem."},{"key":"BFnrrheum201176_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1373\/clinchem.2006.078063","volume":"53","author":"D Coenen","year":"2007","unstructured":"Coenen, D., Verschueren, P., Westhovens, R. & Bossuyt, X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein\/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin. Chem. 53, 498\u2013504 (2007).","journal-title":"Clin. Chem."},{"key":"BFnrrheum201176_CR39","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1186\/ar2008","volume":"8","author":"C Dejaco","year":"2006","unstructured":"Dejaco, C. et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res. Ther. 8, R119 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR40","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3899\/jrheum.080656","volume":"36","author":"N Mutlu","year":"2009","unstructured":"Mutlu, N. et al. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. J. Rheumatol. 36, 491\u2013500 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201176_CR41","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/ard.2009.108456","volume":"69","author":"L Damjanovska","year":"2010","unstructured":"Damjanovska, L. et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann. Rheum. Dis. 69, 730\u2013732 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR42","first-page":"1002","volume":"35","author":"L Innala","year":"2008","unstructured":"Innala, L. et al. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J. Rheumatol. 35, 1002\u20131008 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201176_CR43","first-page":"1658","volume":"34","author":"L Soos","year":"2007","unstructured":"Soos, L. et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J. Rheumatol. 34, 1658\u20131663 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201176_CR44","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/ard.2007.071654","volume":"67","author":"B Vander Cruyssen","year":"2008","unstructured":"Vander Cruyssen, B. et al. Do all anti-citrullinated protein\/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein\/peptide antibody tests in patients with and without rheumatoid arthritis. Ann. Rheum. Dis. 67, 542\u2013546 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR45","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/art.30200","volume":"63","author":"MP van der Linden","year":"2011","unstructured":"van der Linden, M. P. et al. Towards a data-driven evaluation of the 2010 ACR\/EULAR criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? Arthritis Rheum. 63, 1190\u20131199 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR46","first-page":"1691","volume":"30","author":"LM Jansen","year":"2003","unstructured":"Jansen, L. M. et al. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J. Rheumatol. 30, 1691\u20131695 (2003).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201176_CR47","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/ard.2008.091355","volume":"68","author":"O Snir","year":"2009","unstructured":"Snir, O. et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann. Rheum. Dis. 68, 736\u2013743 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.25036","volume":"62","author":"O Snir","year":"2010","unstructured":"Snir, O. et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 62, 44\u201352 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR49","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2010.131102","volume":"70","author":"A Ioan-Facsinay","year":"2011","unstructured":"Ioan-Facsinay, A. et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann. Rheum. Dis. 70, 188\u2013193 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR50","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/art.27439","volume":"62","author":"F Andrade","year":"2010","unstructured":"Andrade, F. et al. Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation. Arthritis Rheum. 62, 1630\u20131640 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ard.2007.080267","volume":"67","author":"EH Halvorsen","year":"2008","unstructured":"Halvorsen, E. H. et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann. Rheum. Dis. 67, 414\u2013417 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/ard.2008.094490","volume":"68","author":"EH Halvorsen","year":"2009","unstructured":"Halvorsen, EH. et al. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. Ann. Rheum. Dis. 68, 249\u2013252 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR53","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/art.27570","volume":"62","author":"JR Kolfenbach","year":"2010","unstructured":"Kolfenbach, J. R. et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 62, 2633\u20132639 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR54","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1002\/art.23763","volume":"58","author":"A Ioan-Facsinay","year":"2008","unstructured":"Ioan-Facsinay, A. et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 58, 3000\u20133008 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR55","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1073\/pnas.0913054107","volume":"107","author":"AJ Schuerwegh","year":"2010","unstructured":"Schuerwegh, A. J. et al. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 107, 2586\u20132591 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201176_CR56","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1186\/ar3237","volume":"13","author":"H Kokkonen","year":"2011","unstructured":"Kokkonen, H. et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res. Ther. 13, R13 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/ard.2006.058933","volume":"66","author":"A Vannini","year":"2007","unstructured":"Vannini, A. et al. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann. Rheum. Dis. 66, 511\u2013516 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR58","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3899\/jrheum.090338","volume":"36","author":"P Kakumanu","year":"2009","unstructured":"Kakumanu, P. et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming\/erosive arthritis. J. Rheumatol. 36, 2682\u20132690 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201176_CR59","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar2913","volume":"12","author":"O Elkayam","year":"2010","unstructured":"Elkayam, O. et al. The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment. Arthritis Res. Ther. 12, R12 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR60","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/art.23514","volume":"58","author":"P Kakumanu","year":"2008","unstructured":"Kakumanu, P. et al. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 58, 1576\u20131581 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR61","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MM Nielen","year":"2004","unstructured":"Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380\u2013386 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/ard.2005.041376","volume":"65","author":"E Berglin","year":"2006","unstructured":"Berglin, E. et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann. Rheum. Dis. 65, 453\u2013458 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR63","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1086\/516736","volume":"80","author":"H Kallberg","year":"2007","unstructured":"Kallberg, H. et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet. 80, 867\u2013875 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrrheum201176_CR64","first-page":"265","volume-title":"From Pathogenesis to Therapy of Autoimmune Diseases: Autoantigens, Autoantibodies, Autoimmunity","author":"JJBC van Beers","year":"2009","unstructured":"van Beers, J. J. B. C., van Venrooij, W. J. & Pruijn, G. J. M. in From Pathogenesis to Therapy of Autoimmune Diseases: Autoantigens, Autoantibodies, Autoimmunity (eds Conrad, K. et al.) 265\u2013278 (Pabst Science Publishers, Lengerich, 2009)."},{"key":"BFnrrheum201176_CR65","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/ar2384","volume":"10","author":"AH van der Helm-van Mil","year":"2008","unstructured":"van der Helm-van Mil, A. H. & Huizinga, T. W. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res. Ther. 10, 205\u2013212 (2008).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR66","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1471-2474-11-187","volume":"11","author":"MZ Cader","year":"2010","unstructured":"Cader, M. Z., Filer, A. D., Buckley, C. D. & Raza, K. The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis. BMC. Musculoskelet. Disord. 11, 187\u2013191 (2010).","journal-title":"BMC. Musculoskelet. Disord."},{"key":"BFnrrheum201176_CR67","doi-asserted-by":"publisher","first-page":"R133","DOI":"10.1186\/ar2022","volume":"8","author":"M Pedersen","year":"2006","unstructured":"Pedersen, M. et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res. Ther. 8, R133 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR68","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1358\/dnp.2009.22.9.1437962","volume":"22","author":"FJ L\u00f3pez-Longo","year":"2009","unstructured":"L\u00f3pez-Longo, F. J., S\u00e1nchez-Ram\u00f3n, S. & Carre\u00f1o, L. The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors? Drug News Perspect. 22, 543\u2013548 (2009).","journal-title":"Drug News Perspect."},{"key":"BFnrrheum201176_CR69","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.22525","volume":"56","author":"H van Dongen","year":"2007","unstructured":"van Dongen, H. et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56, 1424\u20131432 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR70","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1186\/ar3190","volume":"12","author":"TR Mikuls","year":"2010","unstructured":"Mikuls, T. R. et al. Anti-citrullinated protein antibody (ACPA) in rheumatoid arthritis: influence of an interaction between HLA-DRB1 shared epitope and a deletion polymorphism in glutathione S-transferase in a cross-sectional study. Arthritis Res. Ther. 12, R213 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR71","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2009.120899","volume":"70","author":"H Kallberg","year":"2011","unstructured":"Kallberg, H. et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann. Rheum. Dis. 70, 508\u2013511 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.27272","volume":"62","author":"SY Bang","year":"2010","unstructured":"Bang, S. Y. et al. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum. 62, 369\u2013377 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR73","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/ar1184","volume":"6","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar, E. R. & van Venrooij, W. J. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res. Ther. 6, 107\u2013111 (2004).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR74","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ard.2008.105767","volume":"69","author":"WH Bos","year":"2010","unstructured":"Bos, W. H., Dijkmans, B. A., Boers, M., van de Stadt, R. J. & van Schaardenburg, D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann. Rheum. Dis. 69, 571\u2013574 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR75","doi-asserted-by":"publisher","first-page":"R76","DOI":"10.1186\/ar2995","volume":"12","author":"MD Mjaavatten","year":"2010","unstructured":"Mjaavatten, M. D. et al. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis. Arthritis Res. Ther. 12, R76 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR76","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1172\/JCI25422","volume":"116","author":"KA Kuhn","year":"2006","unstructured":"Kuhn, K. A. et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 116, 961\u2013973 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201176_CR77","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1084\/jem.20081862","volume":"206","author":"H Uysal","year":"2009","unstructured":"Uysal, H. et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 206, 449\u2013462 (2009).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201176_CR78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4049\/jimmunol.0901639","volume":"184","author":"PP Ho","year":"2010","unstructured":"Ho, P. P. et al. Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. J. Immunol. 184, 379\u2013390 (2010).","journal-title":"J. Immunol."},{"key":"BFnrrheum201176_CR79","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.23284","volume":"58","author":"C Clavel","year":"2008","unstructured":"Clavel, C. et al. Induction of macrophage secretion of tumor necrosis factor \u03b1 through Fc\u03b3 receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 58, 678\u2013688 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.23148","volume":"58","author":"M van Oosterhout","year":"2008","unstructured":"van Oosterhout, M. et al. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum. 58, 53\u201360 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR81","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.24622","volume":"60","author":"LA Trouw","year":"2009","unstructured":"Trouw, L. A. et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 60, 1923\u20131931 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.30081","volume":"63","author":"J Sokolove","year":"2010","unstructured":"Sokolove, J., Zhao, X., Chandra, P. E. & Robinson, W. H. Immune complexes containing citrullinated fibrinogen co-stimulate macrophages via Toll-like receptor 4 and Fc\u03b3 receptor. Arthritis Rheum. 63, 53\u201362 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR83","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/ng.480","volume":"41","author":"H Mahdi","year":"2009","unstructured":"Mahdi, H. et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated \u03b1-enolase in the etiology of rheumatoid arthritis. Nat. Genet. 41, 1319\u20131324 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrrheum201176_CR84","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/ard.2009.121160","volume":"69","author":"K Visser","year":"2010","unstructured":"Visser, K. et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann. Rheum. Dis. 69, 1333\u20131337 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201176_CR85","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1002\/art.27552","volume":"62","author":"N Wegner","year":"2010","unstructured":"Wegner, N. et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 62, 2662\u20132672 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR86","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/ar3000","volume":"12","author":"P Mangat","year":"2010","unstructured":"Mangat, P., Wegner, N., Venables, P. J. & Potempa, J. Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis? Arthritis Res. Ther. 12, 209\u2013217 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201176_CR87","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JC Edwards","year":"2001","unstructured":"Edwards, J. C. & Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40, 205\u2013211 (2001).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201176_CR88","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge, G. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146\u20132154 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201176_CR89","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/bies.10357","volume":"25","author":"ER Vossenaar","year":"2003","unstructured":"Vossenaar, E. R., Zendman, A. J., van Venrooij, W. J. & Pruijn, G. J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25, 1106\u20131118 (2003).","journal-title":"Bioessays"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.76.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.76","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2011.76.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T10:30:27Z","timestamp":1712485827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2011.76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,7]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["BFnrrheum201176"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2011.76","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,7]]}}}